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Background: This study aimed to explore changes in clinical epidemiology and genotype distribution and their
association among hospitalized children with rotavirus gastroenteritis after the introduction of vaccines.
Methods: Between November 2010 and October 2014, hospitalized children with acute gastroenteritis were
enrolled. Rotavirus genotypes were confirmed through reverse transcription-polymerase chain reaction (RT-PCR),
semi-nested PCR, and sequencing. Clinical information including vaccination status and the modified Vesikari scores
were collected.
Results: Among 179 children with rotavirus infection, nineteen (10.6 %) were completely vaccinated. During
the study period, the number of children between three and 23 months of age decreased significantly
compared to the number of children older than 24 months of age (P = 0.010), who showed lower diarrhea
severity (duration, P = 0.042; frequency, P = 0.021) but higher vomiting severity (P = 0.007, 0.036) compared to
the former. Vaccination status was also significantly associated with lower vomiting severity after adjustment
for age (frequency only, P = 0.018). The predominant genotypes were G2P[4] (18.4 %), G1P[8] (14.5 %), and
G1P[4]P[8] (12.8 %), and the prevalence of genotypes with uncommon and mixed combinations was more
than 50 %. Children infected with G2P[4] strains tended to be older (P = 0.005) and had more severe
vomiting (P = 0.018, 0.006) than those with G1P[8].
Conclusions: Increase in age of infected, hospitalized children was accompanied by change in clinical severity
during 2011–2014 after the introduction of vaccines in Seoul. Clinical severity was also associated with
vaccination status and genotype. Long-term large scale studies are needed to document the significance of
the increase in genotypes of uncommon and mixed combinations.
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Currently, rotavirus vaccination plays a key role in pro-
tecting children against rotavirus-related hospitalizations
in countries implementing rotavirus vaccination [1–3].
In Korea, two rotavirus vaccines, RotaTeq (Merck and
Company, Whitehouse Station, NJ, USA) and Rotarix
(GlaxoSmithKline Biologicals, Rixensart, Belgium) were
introduced in 2007 and 2008, respectively [1, 4]. Al-
though rotavirus vaccines are recommended but not
compulsory, the rate of individuals who had received
two or three doses of a rotavirus vaccine was reported to
be 65.6 % in Seoul and 52.4 % nationwide (2013 Korean
National Immunization Survey, http://www.cdc.go.kr).
As a result, the proportion of rotavirus infection among
hospitalized children with gastroenteritis has been de-
creasing remarkably [2, 5]. According to a recent Korean
Center for Disease Control report (http://www.cdc.go.kr),
the incidence of rotavirus gastroenteritis was lower than
that of norovirus in 2015. The effectiveness of vaccination
against rotavirus-related hospitalization was suggested in
six Asian countries including Korea [6]. However, rota-
virus gastroenteritis is still a major cause of illness requir-
ing hospitalization even among rotavirus-vaccinated
children. In addition, there is still debate on whether di-
versity of rotavirus strains contributes to low vaccine effi-
cacy [7, 8]. Thus, in addition to efforts to increase
vaccination rates, ongoing surveillance of rotavirus geno-
types is necessary, particularly in children with vaccine
failure [9].
Regarding the other notable changes in clinical epi-
demiology after the introduction of rotavirus vaccines, a
few studies reported patterns of seasonal change or age
change in addition to decreased overall prevalence of
rotavirus infection [2, 5, 10]. A delay of the rotavirus
season by 2–3 months was observed in Seoul in a multi-
center study during 2007–2010 [2]. A few single-center
studies in the Korean literature reported that the age of
children with rotavirus infection in Seoul or its suburbs
increased significantly between 2008 and 2013 compared
to the pre-vaccine era [5, 10]. It is unclear whether these
changes have been consistent and ongoing. Before the
introduction of rotavirus vaccines, rotavirus gastroenter-
itis usually occurred in children less than 24 months of
age and presented with the most severe clinical manifes-
tations including diarrhea among all types of viral
gastroenteritis [11]. Because severe diarrhea is usually
believed to be prevalent in younger children [11], the
shift of infected age to rotavirus infection might be ac-
companied by changes in clinical manifestation such as
diarrheal severity of rotavirus gastroenteritis. In addition,
although debatable, clinical factors such as age and se-
verity of gastroenteritis have also been associated with
certain genotypes according to several studies from the
pre-vaccine era and, in countries without rotavirusvaccination programs in recent years [12–15]; thus,
changes in clinical epidemiology might be accompanied
by changes in molecular epidemiology. In previous
studies, this association was often observed when the
distribution of major circulating genotypes underwent
changes [13].
Determination of circulating rotavirus genotypes is
based on characterization of the capsid-protein-coding
genes VP7 (G genotype) and VP4 (P genotype). To date,
there are 27 G and 37 P genotypes have been identified
(http://rotac.regatools.be/classificationinfo.html). Among
them, five G genotypes (G1-G4, and G9) and three P ge-
notypes (P[4], P[6], and P[8]) are most frequently de-
tected. Surveillance by the World Health Organization
(WHO) reported that five combined G/P genotypes
(G1P[8], G2P[4], G3P[8], G4P[8], and G9P[8]) were con-
sidered globally prevalent during 2009-2012 [1]. How-
ever, there is regional and temporal variation in the most
prevalent genotypes. Studies have shown that 70–90 %
of all typeable genotypes in Korea belong to one of the
five most common combined G/P genotypes or G4P[6]
[16–20]. Between the years 1989 and 2009, the most
prevalent genotype combination was G1P[8], though
there were temporal changes in genotype predominance.
For example, G1P[8] was predominant during 1987–
2000 [21] and again between 2004 and 2009 [20, 22, 23].
G2P[4] and G4P[6], which occurred mainly in neonates,
were reported to be the most common strains during
the intervening period, 2000–2003 [24]. G9 was first de-
tected in 2002 and was identified in consecutive seasons
mostly as G9P[8] [22, 23, 25], becoming the fifth most
common genotype in Korea [17, 26]. After the introduc-
tion of rotavirus vaccines, G1P[8] has remained predom-
inant, however, the prevalence of G2P[4] seemed to have
increased around 2013 in Korea [27, 28]. especially in
Seoul, compared to the early vaccination period, al-
though only a few studies on the surveillance of geno-
types are available in the literature [27–29].
Therefore, this study explored changes in the clin-
ical epidemiology and genotype distribution among
rotavirus-infected children from a single hospital in
the southwestern area of Seoul between 2011 and 2014, a
period corresponding to 4–7 years after the introduction
of rotavirus vaccination. We also examined the correla-
tions between genotypes and clinical factors including age,
clinical severity and vaccination status.
Methods
Patients and clinical information
This study was conducted prospectively in the pediatric
ward of Seoul Metropolitan Government-Seoul National
University Boramae Medical Center in Korea with the ap-
proval of the Seoul Metropolitan Government-Seoul
National University Boramae Medical Center Institutional
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tween November 2010 to October 2014, stool samples
were collected from children hospitalized with a clin-
ical suspicion of acute gastroenteritis (AGE) without
known underlying chronic illnesses with immunosup-
pression within three days of admission. The patients
were admitted via either the emergency department or
outpatient clinics. Informed written consent was ob-
tained from the parents or guardians of each child at
enrollment. Patients were excluded based on the fol-
lowing criteria: failure to obtain permission, insuffi-
cient fecal samples, children with newly diagnosed
chronic illnesses including malnutrition, those with a
final co-diagnosis as other acute febrile illnesses in-
cluding pneumonia, or suspected cases of secondary
infections (nosocomial gastroenteritis) during their
hospital stay.
Clinical information including age of onset, date of
hospitalization, fever, duration and maximum number of
diarrhea episodes, and duration and maximum number
of vomiting episodes before and during hospitalization
and at previous visits before admission (outpatient or
emergency department) were collected. From these re-
cords, modified Vesikari scores [11] were assessed. La-
boratory tests for electrolytes were performed for all
children. For most children (>95 %), a stool test for
white blood cells and Salmonella species (spp.), Shigella
spp., and Cholera spp. were also performed by the hos-
pital laboratory. For children who tested positive for
rotavirus stool antigen, a vaccination history was
obtained from the individual vaccination cards and the
Korean Center for Disease Control website (http://
is.cdc.go.kr), which records histories as part of the na-
tional vaccination program.
Additionally, to compare the results of clinical data from
historical data before the introduction of vaccines in our
hospital, electronic medical records from November 2003
to October 2015 were retrospectively reviewed and ana-
lyzed for the following information: age, date and year,
diagnosis, and results of a rotavirus antigen test.
Stool rotavirus test and genotyping
All stool samples were tested for rotavirus antigen by
the hospital laboratory using the enzyme immunoassay
kit Bioline rotavirus® (SD standard diagnostics, Youngin,
Korea). Stool samples were diluted to 10 % with
phosphate-buffered saline, centrifuged, and stored at
−70 °C until further processing. For fecal specimens with
positive stool antigen tests, viral dsRNA was extracted
from stored samples using the QIAamp Viral RNA Mini
Kit (Qiagen, Hilden, Germany). For genotyping, the ex-
tracted RNA was denatured and reverse transcription
polymerase chain reaction (RT-PCR) was performed by
using the Qiagen OneStep RT-PCR kit (Qiagene, Hilden,Germany). The VP7 gene was amplified by using primer
sets Beg9 and End9 under conditions described previ-
ously [30, 31]. Second-round genotyping was analyzed
using a pool of multiple primer sets aBT1, aCT2, aET3,
aDT4, aAT8, aFT9 and G12, specific to G genotypes 1,
2, 3, 4, 8, 9 and 12, respectively [30–35]. To prevent
known mistyping, additional semi-nested PCR for G3
and G9 typing was performed separately with different
primers, G3 and G9 [36]. Second-round PCR for G5 and
G10 was performed with the reverse primers FT5 and
G10 [33]. The VP4 gene was amplified by using the pri-
mer sets Con3 and Con2 under conditions described
previously [37]. P genotypes were analyzed by semi-
nested PCR using a pool of multiple primer sets 2T1,
3T1, 1T1, 4T1, 5T1, and P11, specific to P genotypes 4,
6, 8, 9, 10, and 11, respectively [32, 37]. For P[4], P[6]
and P[8] genotyping, additional semi-nested PCR was
performed separately with a mentioned primer sets. For
strains that were not P-typeable by genotyping PCR as
mentioned above, the primer sets VP4F and VP4R were
used to amplify for the VP4 gene under previously de-
scribed conditions [38]. Amplification products were ex-
amined by electrophoresis in a 2 % agarose gel and
documented with the Bio-Rad Gel Doc 1000 Documen-
tation System (BioRad, Hercules, CA, USA).
Nucleotide sequencing
For strains that were not G- or P-typeable by genotyping
PCR, semi-nested PCR was performed with VP7 primers
or VP4 primers after first round PCR [32, 38]. The
resulting second-round amplicons were purified using
the QIAquick Gel Extraction Kit (Qiagen) and directly
sequenced using ABI Prism BioDye terminator cycle ver-
sion 3.1 and an automatic DNA sequencer ABI 3730
(Applied Biosystems, Foster City, CA, USA). In addition,
to validate the genotyping, one fecal sample correspond-
ing to each of the G genotypes (G1,G2,G3,G4, and G9)
and P genotypes (P[4], P[6] and P[8]) were sequenced
using first round PCR products or second-round ampli-
cons. The second-round amplicons of four randomly
chosen strains with multiple P genotyping were also se-
quenced to confirm the results. The resulting nucleotide
sequences were analyzed with the Bioedit software pack-
age. Genotypes were determined using the NCBI BLAST
nucleotide search program in the GenBank database.
The sequences of P untypeable strains were submitted
to GeneBank under the accession numbers KR611086-
KR611099.
Statistical analysis
We examined the data for normality by using the
Kolmogorov-Smirnov test for normality. For age-
related analyses, both the monthly age and age groups
(four groups: <3 months, 3–23 months, 24–59
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among years, four seasons were defined like the
following as the rotavirus epidemic starts around
November: 2011 season (November 2010 to October
2011), 2012 season (November 2011 to October
2012), 2013 season (November 2012 to October
2013), and 2014 season (November 2013 to October
2014). For comparison among periods from retro-
spective data, three periods were defined like the fol-
lowing: pre-vaccine period (November 2003 to
October 2006), early vaccine period (November 2007
to October 2010), and the post-vaccine period
(November 2011 to October 2015). Comparisons of
categorical data were evaluated using the Chi-square
test. For age groups and clinical severity-related cat-
egorical data, P value for Linear-by-linear test were
used. Continuous variables were summarized using
the median and interquartile range (IQR). Compari-
sons of continuous data were evaluated using the
Mann–Whitney test or Kruskal-Wallis test. For the
adjustment of genotype-associated factors, data were
analyzed using multiple logistic regression with geno-
types as the dependent variables and season, monthly
age, and vaccination status as explanatory variables.
The analysis using ordered logit models was also per-
formed to determine the cumulative odds ratio for
clinical severity-related factors as dependent variables
and monthly age, vaccination status, and genotype as
explanatory variables. Ordinal logistic regression ana-
lysis was performed using SAS Version 9.2 (SAS
Institute, Cary, NC, USA). All other analyses were
performed using SPSS Version 20.0 (IBM, Chicago,
IL, USA).Fig. 1 Seasonal distribution of rotavirus infection in children (n = 179)Results
Overall prevalence, seasonal variation, and distribution of
age
From 820 samples meeting the inclusion criteria during
the study period, 179 samples (21.8 %) positive for rota-
virus antigen were genotyped. The results of tests for
other pathogen performed in the hospital laboratory
were all negative for 179 samples.
From the retrospective data, the prevalence of rota-
virus infection (352/2185 = 15.8 %, from November
2011 to October 2015) was decreased significantly com-
pared to that of the pre-vaccine period (300/1152 =
25.9 %, from November 2003 to October 2006) and
early-vaccine period (261/1367 = 18.9 %, from November
2007 to October 2010) (P = 0.000). Rotavirus infection
was prevalent between January and May, peaking in
March without significant variation among the four
study seasons (Fig. 1). However, a delay in the peak sea-
son during the 2011–2014 seasons compared to the
pre-vaccine period was observed (Additional file 1:
Figure S1). The median age of the 179 children was
30.0 months [IQR 17.0–50.0], which was similar to the
median age of the 312 children (28.6 months [IQR
14.0–48.0]) from the retrospective data during the
2011–2014 seasons. Of 179 children, 144 (80.4 %) were
under five years of age. The rotavirus infection was
more prevalent in children older than 24 months of age
(n = 108) than those 3–23 months of age (n = 59)
(Table 1).
The age of children infected with rotavirus was not
significantly different between seasons during the
study periods (P = 0.073). However, the number of
children between three and 23 months of age
Table 1 Clinical characteristics of 179 children with rotavirus infection including age, vaccination status and clinical severity
Clinical Parameters Total <3 month 3–23 months 24–59 months ≥60 months P
value*(n = 179) (n = 12) (n = 59) (n = 73) (n = 35)
Ages, months 30 [17.0–50.0] 0.85 [0.6–2.0] 16.5 [12.0–21.5] 37.5 [29.3–45.00] 80.5 [71.5–100.5]
Vaccination status, n (%)
complete 19 (10.6) 0 10 9 0 0.09
rotateq 14 0 10 4 0 0.007
rotarix 5 0 0 5 0 0.179
incomplete 6 4 1 1 0
Modified Vesikari score 12 [11–13] 9 [8.25–12] 12 [11–13] 12 [11–13] 12 [10–13] 0.565
≥11, n (%) 135 (75.4) 4 (33.3) 47 (79.7) 58 (79.5) 26 (74.3) 0.777
Vomiting duration, h, n (%) 0.007
0 21 (11.7) 7 8 5 1
1–24 137 (76.5) 4 50 57 26
25–48 17 (9.5) 1 0 9 7
≥49 4 (2.2) 0 1 2 1
Maximum number of episodes per 24-h, n (%) 0.036
0 21 (11.7) 7 8 5 1
1 21 (12.1) 1 7 9 4
2–4 81 (45.3) 3 30 33 15
≥5 56 (31.3) 1 14 26 15
Diarrhea duration, h, n (%)
0 24 (13.4) 1 4 15 4 0.042
1–96 148 (82.7) 11 51 55 31
97–120 3 (1.7) 0 2 1 0
≥121 4 (2.2) 0 2 2 0
Maximum number of episodes per 24-h, n (%), 0.021
0 24 (13.4) 1 4 15 4
1–3 57 (31.8) 4 16 22 15
4–5 39 (21.8) 4 15 12 8
≥6 59 (33.0) 3 24 24 8
Fever, °C, n (%) 0.791
≤37.0 21 (11.7) 3 4 10 4
37.1–38.4 76 (42.5) 6 27 28 15
38.5–38.9 49 (27.4) 1 18 20 10
≥39.0 33 (18.4) 2 10 15 6
Visit to ER, n (%) 105 (58.7) 7 34 49 15 0.838
Seizure, n (%) 6 (3.4) 1 2 3 0 0.614
Total CO2, mmol/L 17 [15.0–19.0] 20.5 [17.0–23.5] 16 [14.0–18.0] 17 [15.0–9.0] 18 [16.0–21.0] 0.031
*children between 3 and 23 month compared to those more than 24 months
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number of children older than 24 months of age (P =
0.010) (Fig. 2). In addition, the median age of
children with rotavirus infection significantly in-
creased compared to the pre-vaccine or early vaccine
periods (Additional file 2: Figure S2). The prevalenceof the rotavirus infection compared to that of overall
acute gastroenteritis was decreased mostly in chil-
dren between three and 23 months of age, but was
rather increased in children under 3 months of age
and those over 60 months of age (Additional file 3:
Figure S3).
Fig. 2 Age distribution of rotavirus infection during 2011–2014 seasons (n = 179). All age groups, P = 0.073;*, between 3–23 months and more
than 24 months age groups, P = 0.010
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Clinical severity based on a modified Vesikari score is
summarized in Table 1. According to age, the neonate
group had a lower modified Vesikari score than older
age groups (P = 0.001). They also had a shorter duration
of vomiting (P < 0.001), fewer vomit episodes (P < 0.001),
and shorter duration of diarrhea (P = 0.046) than older
age groups. After excluding the neonate group (n = 167),
children more than two years of age had a significantly
longer duration of vomiting (P = 0.007) and a more
vomiting episodes (P = 0.036) than children younger
than two years of age.
For diarrhea-related severity, children less than two
years of age, excluding neonates, had a significantly lon-
ger duration of diarrhea (P = 0.042) and more diarrheal
episodes (P = 0.021) than children older than two years.
There were no differences in other clinical severity-
related factors between the groups.
Clinical manifestations by vaccination status
Excluding six children with incomplete vaccination re-
cords, 173 samples were analyzed for vaccination status.
Of these children, 19 had completed rotavirus vaccin-
ation, 14 with RotaTeq and 5 with Rotarix (Table 1). The
proportion of vaccinated children did not change over
time and was significantly higher in children under five
years of age (17.1 %, 19/111) than in children over
5 years (0 %). The median age of completely vaccinated
children was 23.0 months [IQR 18.0–29.0], and the me-
dian age of unvaccinated children was 32.0 months [IQR
18.0–55.5] (P = 0.025).
As neonatal age significantly affected clinical severity-
related factors, we analyzed data after excluding children
under three months of age (n = 165). Vaccinated children
had shorter durations of vomiting (P = 0.045) and fewervomiting episodes (P = 0.012) (Table 2). There was no
difference in diarrhea-related severity or other clinical
severity including the overall Vesikari scores with vac-
cination status.
Because vomiting-related severity was also affected by
age, the analysis using ordered logit models was per-
formed. Vomiting duration was significantly associated
with monthly age (cumulative odds ratio, c-OR, 1.017;
95 % CI, 1.005–1.029; P = 0.006). However, there was a
significant association between the maximum number of
vomiting episodes per 24 h and vaccination status (c-
OR, 0.339; 95 % CI, 0.138-0.832; P = 0.018).
Overall prevalence and seasonal variation of rotavirus
genotypes
The G genotype was identified in 97.2 % (n = 174) and P
genotype in 97.8 % (n = 175) of samples. G1 was the
most common G genotype (48.0 %, n = 86), followed by
G2 (24.6 %, n = 44), G3 (20.1 %, n = 36), G9 (10.6 %, n =
19), and G4 (3.4 %, n = 6). P[4] was the most prevalent
P genotype (68.2 %, n = 122). P[8] was found in 45.3 %
(n = 81), and P[6] in 3.9 % (n = 7). Co-infections with
P[4] and P[8] genotypes were identified in 19.6 % of
cases (n = 35). In G/P combinations, G2P[4] was the
most prevalent, found in 18.4 % (n = 33) of cases,
followed by G1P[8] (14.5 %, n = 26) and G1P[4]P[8]
(13.4 %, n = 24), although the most common genotypes
were different among seasons (Table 3).
Overall, the five most common WHO combinations
were identified in 41.3 % of cases (n = 74). Conversely,
genotypes with unusual P[4] combinations including
G1P[4], G3P[4] and G9P[4] were prevalent in 24.6 % of
cases (n = 44). Interestingly, G3P[4] and G9P[4] were
more prevalent than G3P[8] and G9P[8]. Co-infection
with mixed G/P genotypes was detected in 28.5 % of
Table 2 Clinical characteristics of 165 children with rotavirus infection according to vaccination status excluding neonates and those
incompletely vaccinated
Clinical Parameters Total Vaccinated Unvaccinated P value
(n = 165) (n = 19) (n = 146)
Ages, months 30.5 [19.8–53.8] 23 [18–29] 34.5 [20.8–57.8] 0.007
Modified Vesikari score 12 [11–13] 12 [11–13] 12 [11–13] 0.887
≥11, n (%) 129 (78.2) 16 (9.7) 113 (68.5) 0.500
Vomiting duration, h, n (%) 0.045
0 13 (7.9) 4 9
1–24 132 (80.0) 14 118
25–48 16 (9.7) 1 15
≥49 4 (2.4) 0 4
Maximum number of episodes per 24-h, n (%) 0.012
0 13 (7.9) 4 9
1 20 (12.1) 2 18
2–4 77 (46.7) 11 66
≥5 55 (33.3) 2 53
Diarrhea duration, h, n (%) 0.852
0 23 (13.9) 1 22
1–96 135 (81.8) 18 117
97–120 3 (1.8) 0 3
≥121 4 (2.4) 0 4
Maximum number of episodes per 24-h, n (%), 0.175
0 23 (13.9) 1 22
1–3 52 (31.5) 5 47
4–5 35 (21.2) 5 30
≥6 55 (33.3) 8 47
Fever, °C, n (%) 0.219
≤37.0 18 (10.9) 0 18
37.1–38.4 70 (42.4) 8 62
38.5–38.9 46 (27.9) 7 39
≥39.0 31 (18.8) 4 27
Visit to emergency room, n (%) 95 (57.6) 11 84 0.976
Seizure, n (%) 5 (3.0) 1 4 0.783
Total CO2, mmol/L 17 [14–19] 17 [14–20] 17 [14.8–19] 0.904
Shim et al. BMC Infectious Diseases  (2016) 16:287 Page 7 of 15cases (n = 51). The proportion of uncommon genotypes
including mixed type was more than 40-50 %, which was
consistent among the four seasons (Table 3). There were
no significant differences in the frequencies of other sin-
gle or multiple G, P, or G/P combinations between
seasons.
Rotavirus genotypes by age
There was no age difference between common, uncom-
mon and/or mixed genotypes. However some G, P or G/
P genotypes showed an age preference (Table 4).Children infected with G1 (median, 22.5 months; [IQR
12.5–34.5]) were younger than children with the G2 (me-
dian, 41.0; [IQR 25.0–61.9]; P = 0.001), and G9 (median,
39.0 months; [IQR 22.5–56.3]; P = 0.010) genotypes after
exclusion of G and P type co-infection cases. Children in-
fected with P[4] (median, 31.5 months [IQR 21.5–53.8])
were older than children with P[8] (median, 26.0 months
[IQR 15.3–42.1; P = 0.049) after exclusion of G and P type
co-infection cases. However, the age preference of the
aforementioned genotypes was not significant after adjust-
ment for seasons in logistic regression analysis.
Table 3 Distribution of group A rotavirus G/P genotypes during the fourth to seventh year after the introduction of vaccines, n (%)
Nov 2010–Oct-11 Nov 2011–Oct-12 Nov 2012–Oct-13 Nov 2013–Oct-14 Total
Common genotypes
G2P[4] 8 (18.6) 1 (4.8) 17 (22.4) 7 (17.9) 33 (18.4)
G1P[8] 5 (11.6) 8 (38.1) 12 (15.8) 1 (2.6) 26 (14.5)
G3P[8] 3 (7.0) 1 (4.8) 3 (3.9) 2 (5.1) 9 (5.0)
G9P[8] 1 (2.3) 2 (9.5) 1 (1.3) 1 (2.6) 5 (2.8)
G4P[6] 0 0 0 1 (2.6) 1 (0.6)
G4P[8] 1 (2.3) 0 0 0 1 (0.6)
subtotal 18 (41.9) 12 (57.1) 33 (43.4) 12 (30.8) 75 (41.9)
Uncommon genotypes
G3P[4] 3 (7.0) 4 (19.0) 10 (13.2) 2 (5.1) 19 (10.6)
G1P[4] 4 (9.3) 0 4 (5.3) 10 (25.6) 18 (10.1)
G9P[4] 2 (4.7) 1 (4.8) 2 (2.6) 2 (5.1) 7 (3.9)
G1P[6] 0 0 1 (1.3) 1 (2.6) 2 (1.1)
G2P[8] 0 0 1 (1.3) 0 1 (0.6)
subtotal 9 (20.1) 5 (23.8) 18 (23.7) 15 (38.4) 47 (26.3)
Multiple genotypes
G1P[4]P[8] 8 (18.6) 0 9 (11.8) 7 (17.9) 24 (13.4)
G1G2P[4] 2 (4.7) 1 (4.8) 3 (3.9) 1 (2.6) 7 (3.9)
G9P[4]P[8] 0 2 (9.5) 0 2 (5.1) 4 (2.2)
G3P[4]P[8] 0 0 3 (3.9) 1 (2.6) 4 (2.2)
G1G4P[6] 1 (2.3) 0 1 (1.3) 1 (2.6) 3 (1.7)
G1G3P[4]P[8] 1 (2.3) 0 1 (1.3) 0 2 (1.1)
G1G9P[8] 0 0 2 (2.6) 0 2 (1.1)
G1G3P[8] 0 0 1 (1.3) 0 1 (0.6)
G1G4P[8] 1 (2.3) 0 0 0 1 (0.6)
G2G3P[4] 1 (2.3) 0 0 0 1 (0.6)
G2P[4]P[8] 1 (2.3) 1 (4.8) 0 0 2 (1.1)
subtotal 15 (34.9) 4 (19.0) 20 (26.3) 12 (30.8) 51 (28.5)
nontypeable
none 1 (2.3) 0 2 (2.6) 0 3 (1.7)
P[4] 0 0 2 (2.6) 0 2 (1.1)
G9 0 0 1 (1.3) 0 1 (0.6)
subtotal 1 (2.3) 0 5 (6.5) 0 6 (3.4)
Total 43 (100) 21 (100) 76 (100) 39 (100) 179 (100)
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types were G1P[4] and G1G4P[6] in neonates (both
27.3 %, n = 3), G1P[8] at 3–23 months (20.0 %, n = 12),
G2P[4] at 24–59 months (21.9 %, n = 16), and G2P[4] and
G1P[4]P[8] at ≥60 months (both 28.6 %, n = 10). The
prevalence of G2P[4], G1P[4]P[8], and untypeable type
was significantly higher in older age groups (P = 0.002,
0.010, and 0.025 respectively). G1G4P[6] was identified
only in neonates (P < 0.001) (Table 2). The age of children
infected with G2P[4] (median, 41.5 months [IQR 25.0–62.75]) or G1P[4]P[8] (median, 44.5 months [IQR 28.5–
78.5]) was significantly older than G1P[8]-infected chil-
dren (median, 22.25 months [IQR 13.88–30.63]; P = 0.001
and P = 0.005, respectively). Compared to G1P[8], this age
preference for older children was still significant after
adjusting for seasons and vaccination status in the G2P[4]
(adjusted odds ratio, a-OR of monthly age, 1.042; 95 %
confidence interval, CI, 1.010–1.075; P = 0.011) and
G1P[4]P[8] (a-OR, 1.043; 95 % CI, 1.009–1.077; P = 0.012)
genotypes.
Table 4 Distribution of group A rotavirus G/P genotypes by age groups, n (%)
<3 months 3–23 months 24–59 months ≥60 months Total P value*
Common genotypes
G2P[4] 0 7 (21.2) 16 (48.5) 10 (30.3) 33 (18.4) 0.002
G1P[8] 2 (7.7) 12 (46.2) 10 (38.5) 2 (7.7) 26 (14.5) 0.050
G3P[8] 0 5 (55.6) 3 (33.3) 1 (11.1) 9 (5.0) 0.506
G9P[8] 0 1 (20.0) 2 (40.0) 2 (40.0) 5 (2.8) 0.126
G4P[6] 1 0 0 0 1 (0.6)
G4P[8] 0 0 1 0 1 (0.6)
subtotal 3 25 32 15 75 (41.9) 0.377
Uncommon genotypes
G3P[4] 0 7 (36.8) 12 (63.2) 0 19 (10.6) 0.992
G1P[4] 3 (16.7) 6 (33.3) 6 (33.3) 3 (16.7) 18 (10.1) 0.329
G9P[4] 0 3 (42.9) 2 (28.6) 2 (28.6) 7 (3.9) 0.400
G1P[6] 1 1 0 0 2 (1.1) 0.023
G2P[8] 0 0 1 0 1 (0.6)
subtotal 4 17 21 5 47 (26.8) 0.235
Multiple genotypes
G1P[4]P[8] 2 (8.3) 3 (12.5) 9 (37.5) 10 (41.7) 24 (13.4) 0.010
G1G2P[4] 0 4 (57.1) 2 (28.6) 1 (14.3) 7 (3.9) 0.104
G9P[4]P[8] 0 1 (25) 3 (75) 0 4 (2.2)
G3P[4]P[8] 0 2 (50) 2 (50) 0 4 (2.2)
G1G4P[6] 3 (100) 0 0 0 3 (1.7) 0.006
G1G3P[4]P[8] 0 2 0 0 2 (1.1)
G1G9P[8] 0 1 1 0 2 (1.1)
G1G3P[8] 0 1 0 0 1 (0.6)
G1G4P[8] 0 1 0 0 1 (0.6)
G2G3P[4] 0 0 0 1 1 (0.6)
G2P[4]P[8] 0 2 0 0 2 (1.1)
subtotal 5 17 17 12 51 (28.5) 0.707
nontypeable
none 0 0 2 1 3 (1.7)
P[4] 0 0 0 2 2 (1.1)
G9 0 0 1 0 1 (0.6)
Subtotal 0 0 3 3 6 (3.4) 0.025
Total 12 59 73 35 179 (100)
*compared to other genotypes
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There were no significant differences between the two
groups according to the vaccination status in the fre-
quencies of common, uncommon, mixed genotypes, or
combinations of G/P genotypes according to vaccination
status (Additional file 4: Table S1).
However, among single G/P genotypes, G9 genotype
was detected more frequently in the vaccinated group
than in the unvaccinated group (n = 5/19; 27.8 % vs n =
14/154; 9.3 %, respectively; P = 0.020) (Additional file 5:Table S2). The association with G9 and vaccination sta-
tus was still significant (a-OR of vaccination, 5.261;
95 % CI, 1.477–18.734; P = 0.010) after adjustment for
seasons and age (a-OR of monthly age, 1.014; 95 % CI,
0.9996–1.028; P = 0.036) in multiple logistic regression.
Rotavirus genotypes and clinical severity
As neonatal age significantly affected clinical severity-
related factors, we analyzed data after excluding children
under three months of age (n = 167). There was no
Table 5 Clinical characteristics of G1P[8], G2P[4], and G1P[4]P[8] in 167 children more than 3 months of age
Clinical G1P[8] G2P[4] G1P[4]P[8] Pvalue* P value** P value***
(n = 24) (n = 33) (n = 22)
Ages, median months 24.0 [14.5–31.5] 42.0 [25.0–62.5 45.0 [29.5–79.0] 0.005 0.003 0.122
Complete vaccination, n (%) 2 (8.3) 3 (9.1) 1 (4.5) 0.921 0.344 0.529
Modified Vesikari score, median 11 [10–12] 12 [11–13] 12 [10–14] 0.077 0.230 0.889
Modified Vesikari score≥ 11, n (%) 17 (70.8) 27 (81.8) 16 (72.7) 0.333 0.888 0.428
Vomiting duration, h, n (%) 0 5 (20.8) 0 2 (9.1) 0.018 0.165 0.535
1–24 17 (70.8) 27 (81.8) 16 (72.7)
25–48 2 (8.3) 5 (15.2) 3 (13.6)
≥ 49 0 1 (3.0) 1 (4.5)
Maximum number of episodes per 24-h, n (%) 0 5 (20.8) 0 2 (9.1) 0.006 0.091 0.428
1 5 (20.8) 3 (9.1) 2 (9.1)
2–4 9 (37.5) 16 (48.5) 10 (45.5)
≥ 5 5 (20.8) 14 (42.4) 8 (36.4)
Diarrhea duration, h, n (%) 0 2 (8.3) 6 (18.2) 3 (13.6) 0.180 0.973 0.283
1–96 21 (87.5) 27 (81.8) 17 (77.3)
97–120 1 (4.2) 0 1 (4.5)
≥ 121 0 0 1 (4.5)
Maximum number of episodes per 24-h, n (%), 0 2 (8.3) 6 (18.2) 3 (13.6) 0.161 0.454 0.571
1–3 7 (29.2) 13 (39.4) 8 (36.4)
4–5 6 (25.0) 5 (15.2) 4 (18.2)
≥ 6 9 (37.5) 9 (27.3) 7 (31.8)
Fever, °C, n (%) ≤ 37.0 4 (16.7 %) 3 (9.1 %) 1 (4.5 %) 0.229 0.220 0.978
37.1–38.4 12 (50 %) 14 (42.4 %) 10 (45.5 %)
38.5–38.9 4 (16.7 %) 8 (24.2 %) 7 (31.8 %)
≥ 39.0 4 (16.7 %) 8 (24.2 %) 4 (18.2 %)
Visit to emergency department, n (%) 15 (62.5) 17 (51.5) 10 (45.5) 0.413 0.252 0.663
Seizure, n (%) 1 (4.2) 1 (3.0) 0 0.156 0.338 0.414
Total CO2, median mmol/L 16.0 [14.0–18.0] 17.0 [14.5–18.5] 17.5 [14.8–19.0] 0.769 0.244 0.337
*G2P[4] compared to G1P[8]
**G1P[4]P[8] compared to G1P[8]
***G2P[4] compared to G1P[4]P[8]
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uncommon and mixed genotypes. However, some clin-
ical severity was significantly different among some G, P
or G/P genotypes (Table 5).
Children (n = 167) infected with the G2 genotype pre-
sented with longer durations of vomiting (P = 0.030) and
more vomiting episodes (P = 0.007) than those infected
with G1, after exclusion of G/P co-infection cases. Chil-
dren infected with the P[8] genotype had longer dura-
tions of diarrhea (P = 0.025), but not more diarrheal
episodes (P = 0.070) than those infected with the P[4]
genotype, after exclusion of G/P co-infection cases.
There were no differences in clinical severity among
other G or P genotypes.
For G/P combinations, we compared G1P[8] and other
major G/P combinations, including G2P[4]. Childrenwith G2P[4] were older (P = 0.005) and had longer dura-
tions of vomiting (P = 0.018), and more vomiting epi-
sodes (P = 0.006) than children with G1P[8]. Modified
Vesikari scores did not show any significant differences
between two genotypes (P = 0.077). Children with
G1P[4]P[8] were older than those with G1P[8] (P =
0.003). However, there were no differences in the clinical
manifestations of G1P[4]P[8] and G1P[8] (Table 5). Nei-
ther were there any significant differences in clinical
manifestations between G1P[8] and other G/P combina-
tions, including G1P[4], G3P[4], and G9P[4].
As older age, unvaccinated status, and infection with
the G2P[4] genotype compared to G1P[8] were all sig-
nificantly associated with greater vomiting-related clin-
ical severity, the analysis using ordered logit models was
performed. Genotype was found to be a significant factor
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after adjustment for age, 4.89; 95 % CI, 1.242–19.258;
P = 0.023) and the maximum frequency of vomiting (c-OR
of G2P4 genotype after adjustment for vaccination status,
4.68; 95 % CI, 1.658–13.232; P = 0.004); monthly age
(c-OR for vomiting duration, 1.015; 95 % CI, 1.001–1.028;
P = 0.031) and vaccination status (c-OR for maximum fre-
quency of vomiting, 0.184; 95 % CI, 0.066–0.514; P-0.001)
also remained as significant factors for vomiting-related
severity after adjustment for genotypes.
Discussion
This study spanned the fourth to seventh years of sur-
veillance of rotaviruses in a single hospital in southwest-
ern area of Seoul after the introduction of rotavirus
vaccines in Korea. Our report contains two notable find-
ings; firstly, it demonstrated a significant increase in the
age of hospitalized children with the rotavirus infection
after the introduction of the rotavirus vaccination pro-
gram in Seoul, Korea. We further showed that this shift
in infected age could be accompanied by a change in
vomiting and diarrheal severity. Secondly, a distinctive
change in the distribution of rotavirus genotypes, includ-
ing a prominent increase in genotypes of uncommon
and mixed combinations, was observed during the study
periods. A relative increase of the G2P[4] genotype was
also observed, which was significantly associated with
age and clinical severity in this population. Although
these are the results from a single hospital with a modest
number of fecal samples, a considerable number of find-
ings in clinical and molecular epidemiology share similar
trends observed in other single center studies from
Seoul and some multi-center Korean studies conducted
in the post-vaccine period [2, 5, 10, 27–29]. To our
knowledge, this is one of the first attempts to explore
the link between age, clinical severity and genotypes in a
region that adopted the rotavirus vaccination, which
may contribute to an integrated understanding of the
changing patterns in both clinical and molecular epi-
demiology for rotavirus gastroenteritis after the intro-
duction of vaccines.
The finding of the shift of infected age tended to be
more prominent the further in time it was separated
from the year in which vaccines were introduced, which
was consistent with the results of a few previous Korean
studies [2, 10]. In a multicenter study, the prevalence of
rotavirus infection compared to that of overall acute
gastroenteritis was examined during 2007–2010. The ra-
tio of children between less than 24 months old to more
than 24 months old decreased from 1.2 (54.46 %/
46.18 %) in 2007 to 0.7 (6.35 %/8.68 %) in 2010 [2]. In
another, a single hospital study performed in the suburbs
of Seoul, the median age of children with rotavirus infec-
tion increased to 3.6 years in 2012 from 1.7 years in2007 [10]. Although less prominent, a similar shift in
age from 14.9 months in the pre-vaccine period to
19 months in the post-vaccine period was also observed
in a Greek study [39], in which the rotavirus vaccination
rate was 25–30 %. The shift in infected age may partly
reflect the protective effect of vaccines against severe
rotavirus infection in vaccinated young children, who
were the main focus of the newly introduced rotavirus
vaccines in contrast to older children, who could not be
vaccinated due to age restrictions or lack of information
regarding the vaccines. However, the prevalence of the
rotavirus infection, compared to that of overall acute
gastroenteritis, actually increased significantly in chil-
dren, especially those older than 60 months of age,
compared to that of the pre-vaccine era, although it de-
creased significantly in the whole population (Additional
file 3: Figure S3). We hypothesize that the changing dis-
tribution of the rotavirus genotypes, such as an increase
of G2P[4] and G1P[4]P[8] that show older age prefer-
ence in our study, may also be associated with this pos-
sibly transient increase in the age group of infected
children, in addition to the age group deviation of vac-
cine recipients.
Interestingly, we found a significant association be-
tween clinical severity and age partly due to shift in age,
which could produce a sufficient number of relatively
old age children (including approximately 20 % of chil-
dren older than 60 months) comparable to that of youn-
ger age children. Vomiting-related severity increased
and diarrhea-associated severity decreased with age in
rotavirus gastroenteritis. Although it is controversial if
and how clinical severity is associated with age [40, 41],
this result is compatible with our speculation, as pedia-
tricians in clinical practice, that vomiting has become
the main symptom of rotavirus gastroenteritis, with diar-
rheal severity becoming less prominent in the last few
years. This may be associated with an increase in patient
age after the introduction of vaccines. In our study, clin-
ical severity was also related to vaccination status, al-
though the difference was not very impressive, as well as
different genotypes in addition to age. On the basis of
the distribution of these factors in the study subjects and
the clinical severity-related factors examined, we specu-
late that either older (vomiting-related severity) or youn-
ger (diarrhea-related severity) age could be associated
with greater clinical severity, or, there could be no asso-
ciation between age and overall severity (as measured by
the modified Vesikari score) [40, 41].
Regarding genotype distribution, two notable changes
were observed during the study period. First, G2P[4]
was the most prevalent genotype overall, though there
was seasonal variation. The predominance of G2P[4],
has been reported recently in many countries with or
without vaccination including Korea [28, 42]. This
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vaccine pressure. Second, the prevalence of P[4] combi-
nations with G1, G3 and G9 (G1P[4], G3P[4] and
G9P[4]), along with their mixed P genotype combina-
tions G1P[4]P[8], G3P[4]P[8], and G9P[4]P[8] increased
to more than 40 % among typeable strains, although the
G1, G3, and G9 genotypes were mostly found in com-
bination with P[8] in the past [43]. As a result, the
prevalence of the five most common WHO combina-
tions was less than 50 %, which was relatively consistent
during all four seasons. Until recently, most studies in
Korea identified the five most common WHO combina-
tions plus G4P[6] (mainly in neonates) in more than 70–
90 % of typeable strains [16–20]. The genotypes of
mixed G/P combinations were not prevalent in most
studies. In a pre-vaccine era (2000–2007) study in Korea,
85.3 % were 5 common genotypes plus G4P[6], and un-
common genotypes and mixed genotypes were 11.8 %
(5.82 % and 5.97 %, respectively) [44]. In other meta-
analysis during 1989–2009 in Korea, 81.8 % were com-
mon genotypes [26]. However, a recent single hospital
study in the northeastern area of Seoul reported a high
prevalence of genotypes with non-WHO combinations
and mixed G/P combinations similar to ours, in which
the most prevalent G/P genotype was G9P[4] [29]. It has
been known that the occurrence of mixed infection by
more than two strains with different genotype combina-
tions could encourage genotype reassortment and the
appearance of strains with uncommon genotype combi-
nations [45, 46]. Although increases in naturally occur-
ring reassortment have often been reported [45], the
unusual increase in uncommon and mixed genotypes
observed in our study might reflect one of the responses
to the introduction of rotavirus vaccines. Increases in
previously uncommon G/P combinations, especially
those not included in the current vaccines, have also
been observed in other countries [9, 47–49]: In a recent
study in Brazil, an increase of G3P[6] was reported fol-
lowing the introduction of the G1P[8] attenuated vac-
cine [49]. In the United States, an increase of G12 and a
relatively low vaccine efficacy against this genotype were
reported [48]. Although it has not been determined
whether vaccine-associated selection pressure may play
a role in these observations [9], studies have reported
that increases in uncommon G/P combinations tend to
coincide with the implementation of a rotavirus vaccin-
ation program [47–49]. Future large scale studies for
prolonged periods, both covering clinical and molecular
epidemiology, are needed to document the significance
of the increase of genotypes of uncommon and mixed
combinations in our population.
In our study, the distinctive difference among the
major distribution of genotypes was not observed be-
tween unvaccinated children or those with vaccinefailure: the prevalence of genotypes of uncommon or
mixed type combinations or major G/P combinations
such as G2P[4] was not significantly different between
the two groups. Although the proportion of G9 geno-
type was significantly higher in the vaccinated group,
the significance of this observation could not be de-
termined because of a relatively low significant P
value (P = 0.010) in a small number of vaccinated
children (n = 19). In previous two Korean studies, al-
though the number of vaccinated children was also
small, there was no significant difference in the geno-
type distribution between vaccinated children and
those unvaccinated [27, 28].
We found a significant relationship between certain
genotypes and clinical factors, including age and vomit-
ing- or diarrhea-related severity. In addition to the well-
known neonatal preference of G4P[6] [50], we found
that G2P[4], G1P[4]P[8], and G9 strains preferentially
infected older children, after adjustment for season and
vaccination status. Among them, G2P[4] was signifi-
cantly associated with greater vomiting-related severity
compared to other genotypes, including G1P[8], beyond
neonatal age. It is not clear why children infected with
strains with G2P[4] showed increased vomiting severity
compared to those infected with G1P[8]. However, the
association between G2P[4] and age or clinical severity
itself is mostly consistent with the results of several
studies from the pre-vaccine era [12, 13, 51] and in
countries without rotavirus vaccination [14, 15]. The lit-
erature suggests that the preference of G2P[4] or G2 to
infect older children and cause greater clinical severity
might be a consequence of a G2 epidemic after a pro-
longed period of nonprevalence [13]. Cross-protective
immunity may be less effective against G2 than other
common G types or G2 may possibly be more virulent
[12, 52]. These speculations are supported by previous
studies on the predominance of G2 in children with sec-
ond episodes of rotavirus gastroenteritis [14] or adult
outbreaks of rotavirus gastroenteritis [52].
In Korea, G2P[4] was prevalent before 2002, with
its incidence decreasing until recently, and was again
prevalent in our study period [24, 28]. Children at
ages that are vulnerable to rotavirus gastroenteritis
(except rotavirus-naïve children) may be more suscep-
tible to G2P[4] stains than G1P[8], which was preva-
lent until recently. Due to rotavirus vaccination,
which began in 2007, many younger children have
protective immunity against most common and pos-
sibly uncommon genotypes. However, many older
children, who usually did not receive rotavirus vaccin-
ation in the early vaccine period due to an age re-
strictions or a lack of information regarding the
vaccine, may have insufficient protective immunity
against G2P[4] strains, probably because of a lack of
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munity against G2P[4] strains compared to other
common genotypes, including G1P[8]. Therefore, in-
fection with G2P[4] strains occur more often in older
children than with G1P[8] and other common geno-
types, influenced by both the G2P[4] epidemic and
vaccines. This association between genotype and age
could also be one of the explanations for the signifi-
cantly older age of unvaccinated children compared
to younger children with vaccine failure in addition
to age group deviation of the vaccine recipients.
There were some limitations in our study. First, this
is not a large-scale multicenter study. Only hospitalized
children at a single hospital were included. With regard
to genotype-related clinical severity, community-based
comparisons may yield more prominent and accurate
differences between genotypes [53]. Second, the num-
ber of vaccinated children was small, so we could not
conclude the genotypic comparison between vaccinated
and unvaccinated groups. On the other side, the low
proportion of vaccinated children in this study might
imply the protective effect of rotavirus vaccine. Third,
tests for co-infections with microbial agents other than
Salmonella spp., Shigella spp., and Cholera spp. were
not performed in our patients. However, a recent
study reported that clinical severity was not affected
by multiple co-infections with other enteric viruses
[42], with rotavirus showing the most severe clinical
manifestations [40]. Finally, other possible risk factors
for severity such as previous breastmilk feeding or
day care center attendance were not considered.
However, children with major potential risk factors
such as malnutrition or underlying chronic illnesses
affecting host immunity were not included in our
study.Conclusions
This prospective hospital-based study revealed that
rotavirus vaccine showed fare efficacy in southwestern
area of Seoul between 2011 and 2014, corresponding to
the fourth to seventh years of rotavirus vaccination,
although rotavirus vaccines were not included in the
national vaccination program. Age of children with
rotavirus gastroenteritis increased significantly after the
introduction of vaccines among hospitalized children in
Seoul, partly suggesting a protective effect of vaccines
in recipients and a possible association between host
age and virus genotypes. Clinical severity of rotavirus
infection was associated with age, vaccination status,
and certain genotypes in this population. Future large
scale studies with long term surveillance of genotypes
are needed to document the significance of the increase
of genotypes of uncommon and mixed combinations.Additional files
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